QT Prolongation and Arrhythmias in Cancer Therapy: A Narrative Review of Mechanistic and Clinical Studies
- 23 May 2026
- journal article
- review article
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 26 (6) , 58
Abstract
Drug-induced QTc prolongation has emerged as a major, preventable cause of malignant ventricular arrhythmias in cancer therapy. This narrative review integrates mechanistic, clinical, and practical insights into QTc prolongation associated with antineoplastic and supportive medications. We outline direct ionic mechanisms, most notably hERG/IKr blockade and PI3K/Akt pathway modulation, as well as indirect contributors, including cytokine-mediated myocarditis, electrolyte disturbances, and structural remodeling. High-risk agents, including arsenic trioxide, vandetanib, nilotinib, sunitinib, and ribociclib, are contrasted with lower-risk alternatives and QT-sparing strategies. Polypharmacy and drug-drug interactions are emphasized as major real-world amplifiers of risk. Among supportive medications, fluoroquinolones, azole antifungals, and certain antiemetics frequently interact with QT-active anticancer agents, whereas beta-lactams, echinocandins, isavuconazole, and palonosetron may represent safer alternatives. We propose a mechanism-to-bedside framework that incorporates baseline ECG and electrolyte assessment, QT-risk stratification, and clear intervention thresholds (QTc ≥ 500 ms or an increase of ≥ 60 ms). Acute management of torsades de pointes, including intravenous magnesium and overdrive pacing, as well as structured hold-and-rechallenge algorithms, is also summarized. Finally, we highlight system-level measures, such as drug interaction stewardship, standardized discharge communication, and clinician education, to shift cardio-oncology practice from reactive arrhythmia management toward anticipatory prevention. This integrative synthesis aims to preserve oncologic efficacy while mitigating arrhythmic risk in modern cancer care. Graphical abstract The alternative text for this image may have been generated using AI. The alternative text for this image may have been generated using AI.Keywords
This publication has 111 references indexed in Scilit:
- Post-marketing surveillance of quizartinib for relapsed or refractory FLT3-ITD-positive acute myeloid leukemia in JapanInternational Journal of Hematology, 2026
- Cardiotoxic Effects Following CAR-T Cell Therapy: A Literature ReviewCurrent Oncology Reports, 2025
- Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 GuidelinesCurrent Oncology Reports, 2023
- Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitorsInternational Journal of Cancer, 2020
- Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and managementCancer Chemotherapy and Pharmacology, 2017
- Development of a risk score for QTc-prolongation: the RISQ-PATH studyInternational Journal of Clinical Pharmacy, 2017
- Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteersSupportive Care in Cancer, 2015
- Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphomaCancer Chemotherapy and Pharmacology, 2015
- A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adultsCancer Chemotherapy and Pharmacology, 2012
- Prolonged QTc Interval and Risks of Total and Cardiovascular Mortality and Sudden Death in the General PopulationArchives of internal medicine (1960), 2004